USPTO serial 97235095
ZYGEL
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- THOMPSON, HEATHER
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ZYGEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sarah Anne Keefe
Sarah Anne Keefe WOMBLE BOND DICKINSON (US) LLP470 ATLANTIC AVENUE, SUITE 600BOSTON, MA 02210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of human and veterinary diseases and disorders, namely, addiction, auditory diseases and disorders, autism, autoimmune diseases and disorders, anxiety, bone diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, cognitive diseases and disorders, dermatological diseases and disorders, diabetic diseases and disorders, endocrine diseases and disorders, gastroenterological diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hepatological diseases and disorders, hormonal diseases and disorders, infectious diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, movement diseases and disorders, muscular diseases and disorders, musculoskeletal diseases and disorders, neurodegenerative diseases and disorders, neurodevelopmental diseases and disorders, oncological diseases and disorders, ophthalmic diseases and disorders, pain, post-traumatic stress, pulmonary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, rheumatological diseases and disorders, psychiatric diseases and disorders, seizure diseases and disorders, sexual dysfunction, speech disorders and diseases, traumatic brain injury, and viral diseases and disorders; Pharmaceutical preparations for the treatment of fragile x syndrome, substance related addiction, autism and autism spectrum disorders, epilepsy, seizure diseases and disorders, anxiety, aphasias, stuttering, post-traumatic stress disorder; all of the foregoing specifically excluding narcolepsy and management of sleep disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 16, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 16, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 16, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 16, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 22, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 22, 2025 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Dec 22, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 1, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 1, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 7, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 7, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 6, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 6, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 27, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 27, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 27, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jun 27, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 3, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 1, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 1, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 1, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 8, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 6, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 6, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 6, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 7, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 13, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 13, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 23, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 7, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 2, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 27, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 27, 2022 | NWAP | NEW APPLICATION ENTERED | — |